Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allele-specific RNA interference for neurological disease.

E Rodriguez-Lebron1, H L Paulson

  • 1Department of Neurology, Carver College of Medicine, Iowa City, IA 52242, USA. edgardo-rodriguez@uiowa.edu

Gene Therapy
|December 16, 2005
PubMed
Summary

RNA interference (RNAi) can silence toxic genes for treating human diseases, especially neurological disorders. New RNAi strategies enhance allele-specific gene silencing for improved therapeutic outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ubiquitin ligase F-box/G-domain protein 1 promotes the degradation of the disease-linked protein torsinA through the ubiquitin-proteasome pathway and macroautophagy.

Neuroscience·2012
Same author

The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease.

The Journal of biological chemistry·2001
Same author

Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila.

Human molecular genetics·2000
Same author

Polyglutamine disease and neuronal cell death.

Proceedings of the National Academy of Sciences of the United States of America·2000
Same author

Toward an understanding of polyglutamine neurodegeneration.

Brain pathology (Zurich, Switzerland)·2000
Same author

Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70.

Nature genetics·1999

Area of Science:

  • Molecular Biology
  • Genetics
  • Neuroscience

Background:

  • RNA interference (RNAi) offers a promising therapeutic strategy for silencing toxic gene expression.
  • Dominant toxic genes causing neurological disorders can be targeted using allele-specific silencing approaches.
  • Recent advancements in RNAi biology provide new opportunities for therapeutic development.

Purpose of the Study:

  • To review current strategies for achieving allele-specific gene silencing via RNAi.
  • To discuss how new insights into small interfering RNA (siRNA) and microRNA (miRNA) processing can enhance RNAi therapy.
  • To explore methods for maximizing the therapeutic benefits of RNAi technology.

Main Methods:

  • Review of existing literature on RNAi and allele-specific silencing.
  • Analysis of recent developments in siRNA and miRNA processing.
  • Discussion of strategies for optimizing RNAi therapeutic efficacy and specificity.

Main Results:

  • Allele-specific RNAi is a viable strategy for targeting dominant toxic genes in neurological diseases.
  • Understanding siRNA and miRNA processing can significantly improve RNAi efficiency and specificity.
  • Several approaches can be employed to maximize the clinical benefits of RNAi-based therapies.

Conclusions:

  • RNAi-based allele-specific gene silencing holds significant therapeutic potential for genetic neurological disorders.
  • Further research into RNAi processing mechanisms will refine the development of targeted RNAi therapies.
  • Optimizing RNAi delivery and specificity is crucial for successful clinical translation.

Related Experiment Videos